The University of Virginia is participating in a national study, funded through the National Institutes of Health (NIH), assessing infection, viral shedding, and transmission risks among college students who receive the Moderna COVID-19 vaccine two-dose series. The study (COVPN 3006) is being conducted to determine the Moderna vaccine’s effectiveness in preventing infection among college students, and to better understand if the vaccine prevents asymptomatic infection and how it reduces the risk of transmission to others.
Interested in volunteering for COVPN 3006? Please review:
- The study will enroll up to 12,000 student volunteers from various U.S. universities.
- UVA plans to enroll approximately 600 UVA student volunteers.
- Half of the study participants, chosen at random, will receive their first dose of the Moderna vaccine immediately, while the other half will receive it in four months.
- Study participants will be compensated up to $590 each, divided into monthly payments, for their full participation in the study.
Ready for next steps? Check your eligibility:
- Enrolled University of Virginia student
- 18 – 26 years of age at time of signed consent to participate in study
- Plan on living in Charlottesville in summer of 2021 (study will end August/September)
- No history of positive COVID-19 test or infection
- Available for prevalence (saliva) testing as required by the Universiy of Virginia through UVA’s Be SAFE program
- Willing to collect and drop off daily nasal swabs (self-collected)
- Willing to complete a daily e-diary
- Willing to attend 4 to 5 study visits (some with blood draws)
If you have already had your first dose of a COVID-19 vaccine, you are not eligible for this study.
Students who would like to volunteer should call (434) 924-5362, press option 3, and leave a voicemail.
All media inquires related to this study, please contact Brian Coy at email@example.com
There is no prohibition on students in the delayed vaccination group receiving a COVID-19 vaccine from another source if they become eligible through state guidelines in the interim.
NOTE: University and UVA Health leaders stress that UVA’s participation in the vaccine study in no way affects the availability or supply of vaccines in the Charlottesville community. Decisions about the rollout of vaccines in the larger community remain with the Virginia Department of Health, working with federal health resources. UVA will play a supporting role in those larger efforts as requested by the VDH.
To read the UVAToday story about this vaccination study, click here.